

Anthony P West

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9198641/publications.pdf>

Version: 2024-02-01

45
papers

10,374
citations

101543

36
h-index

223800

46
g-index

55
all docs

55
docs citations

55
times ranked

13865
citing authors

#	ARTICLE	IF	CITATIONS
1	Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. <i>Science</i> , 2022, 377, .	12.6	120
2	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. <i>Science</i> , 2021, 371, 735-741.	12.6	305
3	Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	25
4	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021, 184, 3205-3221.e24.	28.9	73
5	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. <i>Nature Communications</i> , 2021, 12, 4886.	12.8	65
6	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021, 36, 109760.	6.4	80
7	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. <i>Science Translational Medicine</i> , 2021, 13, eabk1533.	12.4	27
8	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. <i>Nature</i> , 2020, 588, 682-687.	27.8	1,346
9	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020, 584, 437-442.	27.8	1,742
10	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020, 182, 828-842.e16.	28.9	724
11	Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate. <i>ELife</i> , 2020, 9, .	6.0	37
12	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. <i>ELife</i> , 2020, 9, .	6.0	10
13	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019, 50, 1513-1529.e9.	14.3	85
14	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. <i>Nature</i> , 2019, 570, 468-473.	27.8	145
15	Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. <i>Nature Communications</i> , 2018, 9, 1251.	12.8	85
16	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018, 561, 479-484.	27.8	392
17	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	128
18	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. <i>Nature Medicine</i> , 2017, 23, 185-191.	30.7	399

#	ARTICLE	IF	CITATIONS
19	Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. <i>Cell</i> , 2017, 169, 597-609.e11.	28.9	279
20	Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. <i>ELife</i> , 2017, 6, .	6.0	52
21	Structural basis for germline antibody recognition of HIV-1 immunogens. <i>ELife</i> , 2016, 5, .	6.0	68
22	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. <i>Science</i> , 2016, 352, 997-1001.	12.6	263
23	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 906-915.	8.2	188
24	Structure of an HIV-2 gp120 in Complex with CD4. <i>Journal of Virology</i> , 2016, 90, 2112-2118.	3.4	19
25	Antibody engineering for increased potency, breadth and half-life. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 151-159.	3.8	46
26	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015, 161, 1280-1292.	28.9	305
27	Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1. <i>Cell</i> , 2015, 160, 433-446.	28.9	109
28	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. <i>Nature</i> , 2015, 522, 487-491.	27.8	665
29	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. <i>MBio</i> , 2015, 6, .	4.1	25
30	Anti-PolyQ Antibodies Recognize a Short PolyQ Stretch in Both Normal and Mutant Huntingtin Exon 1. <i>Journal of Molecular Biology</i> , 2015, 427, 2507-2519.	4.2	31
31	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. <i>Journal of Experimental Medicine</i> , 2014, 211, 2361-2372.	8.5	79
32	Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy. <i>Cell</i> , 2014, 156, 633-648.	28.9	318
33	Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike. <i>Cell Reports</i> , 2014, 7, 785-795.	6.4	199
34	Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12. <i>Cell Reports</i> , 2013, 5, 1443-1455.	6.4	36
35	Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 10598-10603.	7.1	106
36	Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. <i>Journal of Experimental Medicine</i> , 2013, 210, 1235-1249.	8.5	85

#	ARTICLE	IF	CITATIONS
37	Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. <i>Journal of Experimental Medicine</i> , 2013, 210, 655-663.	8.5	275
38	Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2083-90.	7.1	212
39	Single-Chain Fv-Based Anti-HIV Proteins: Potential and Limitations. <i>Journal of Virology</i> , 2012, 86, 195-202.	3.4	29
40	Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design. <i>Science</i> , 2011, 334, 1289-1293.	12.6	345
41	Evaluation of CD4-CD4i Antibody Architectures Yields Potent, Broadly Cross-Reactive Anti-Human Immunodeficiency Virus Reagents. <i>Journal of Virology</i> , 2010, 84, 261-269.	3.4	34
42	Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7385-7390.	7.1	146
43	Design and Expression of a Dimeric Form of Human Immunodeficiency Virus Type 1 Antibody 2G12 with Increased Neutralization Potency. <i>Journal of Virology</i> , 2009, 83, 98-104.	3.4	49
44	The Chicken Yolk Sac IgY Receptor, a Functional Equivalent of the Mammalian MHC-Related Fc Receptor, Is a Phospholipase A2 Receptor Homolog. <i>Immunity</i> , 2004, 20, 601-610.	14.3	126
45	Crystal Structure and Immunoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor,. <i>Biochemistry</i> , 2000, 39, 9698-9708.	2.5	233